Loading viewer...
investor_presentation
Format: PDF investor_presentation
Fourth Quarter and Full Year 2020 Financial Results February 4, 2021 Ray Scott, President and CEO Jason Cardew, Senior Vice President and CFO
Fourth Quarter and Full Year 2020
Ray Scott, President and CEO
Jason Cardew, Senior Vice President and CFO2Forward-Looking Statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigati on Reform Act of 1995, including state ments regarding anticipated
financial results and liquidity. The words “will,” “may,” “designed to,” “out look,” “believes,” “should,” “antic ipates,” “plans,” “expects,” “i ntends,” “estimates,” “forecasts” and
similar expressions identify certain of these forward-looking statement s. The Company also may provide forward-looking statements in oral statem ents or other written
materials released to the public. All statements contained or incorpor ated in this presentation or in any other public statements that address opera ting performance, events or
developments that the Company expects or anticipates may occur in the future ar e forward-looking statements. Factors that could cause actual result s to differ materially from
these forward-looking statements are discussed in the Company’s Annu al Report on Form 10-K for the year ended December 31, 2019, Quarterly Reports on Form 10-Q for
the quarters ended April 4, 2020, July 4, 2020, and October 3, 2020, and its ot her Securities and Exchange Commission filings. Future operating result s will be based on
various factors, including the impact of COVID-19 on our business and the g lobal economy, actual industry producti on volumes, commodity prices, the impact of restructuring
actions and the Company’s success in implementing its operating strategy.
Information in this presentation relies on assumptions in the Company’s s ales backlog. The Company’s sales backlog reflects anticipated net sales f rom formally awarded
new programs less lost and discontinued programs. The Company enters into c ontracts with its customers to provide production parts generally at the b eginning of a vehicle’s
life cycle. Typically, these contracts do not provide for a specified quantit y of production, and many of these contracts may be terminated by the Comp any’s customers at any
time. Therefore, these contracts do not represent firm orders. Further, the calculation of the sales backlog does not reflect customer price reducti ons on existing or newly
awarded programs. The sales backlog may be impacted by various assumpti ons embedded in the calculation, including vehicle production levels on new p rograms, foreign
exchange rates and the timing of major program launches.
The forward-looking statements in this presentation are made as of the date hereof, and the Company does not assume any obligation to update, amend or c larify them to
reflect events, new information or circumstances occurring after the date hereof.
Non-GAAP Financial Information
This presentation also contains non-GAAP financial information. For addi tional information regarding the Company’s use of non-GAAP financial inf ormation, as well as
Preview truncated — download the full document for the complete content.
investor_presentation
26 Pages
investor_presentation
38 Pages
Tyra Biosciences